Monte Rosa Therapeutics, Inc.
GLUE Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$10.84
2.4%
Revenue
Total sales reported in the income statement.
$124M
63.5%
vs prior year
Operating margin
Operating income as a share of revenue.
โ43.8%
63.4ย pts
Net income
Profit after all expenses, interest and tax.
โ$38.6M
Free cash flow
Cash from operations minus capital spending.
โ$27.5M
172.3%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.1B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
What Monte Rosa Therapeutics, Inc. does
No business description yet.
- Legal name
- Monte Rosa Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 17, 2026
- Accession ยท CIK
- 0001193125-26-109360
0001826457
Revenue and margins
Monte Rosa Therapeutics, Inc. had $124M of revenue in fiscal 2025, up 63.5% on the year before.
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue $0.0M
FY24
Revenue $75.6M
FY25
Revenue $124M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $1.1M
Q2 '24
Revenue $4.7M
Q3 '24
Revenue $9.2M
Q4 '24
Revenue $60.6M
Q1 '25
Revenue $84.9M
Q2 '25
Revenue $23.2M
Q3 '25
Revenue $12.8M
Q4 '25
Revenue $2.8M
Q1 '26
Revenue $4.2M
Q2 '26
Revenue $9.0M
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ107.3%
Net โ96.1%
FCF 50.3%
FY25
Gross โ
Operating โ43.8%
Net โ31.2%
FCF โ22.2%
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ3,284.5%
Net โ3,004.5%
FCF โ3,717.0%
Q2 '24
Gross โ
Operating โ695.3%
Net โ645.6%
FCF โ634.5%
Q3 '24
Gross โ
Operating โ287.8%
Net โ258.9%
FCF โ232.1%
Q4 '24
Gross โ
Operating 21.4%
Net 22.2%
FCF 212.3%
Q1 '25
Gross โ
Operating 51.9%
Net 55.2%
FCF โ55.4%
Q2 '25
Gross โ
Operating โ67.1%
Net โ53.0%
FCF โ157.0%
Q3 '25
Gross โ
Operating โ258.3%
Net โ212.1%
FCF 781.5%
Q4 '25
Gross โ
Operating โ1,787.7%
Net โ1,658.0%
FCF โ1,574.3%
Q1 '26
Gross โ
Operating โ1,188.5%
Net โ1,057.1%
FCF โ932.0%
Q2 '26
Gross โ
Operating โ547.8%
Net โ483.9%
FCF โ544.6%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$35.9M
FY21
Net income โ$74.0M
FY22
Net income โ$109M
FY23
Net income โ$135M
FY24
Net income โ$72.7M
FY25
Net income โ$38.6M
Q3 '23
Net income โ$34.9M
Q4 '23
Net income โ$33.3M
Q1 '24
Net income โ$32.0M
Q2 '24
Net income โ$30.3M
Q3 '24
Net income โ$23.9M
Q4 '24
Net income $13.4M
Q1 '25
Net income $46.9M
Q2 '25
Net income โ$12.3M
Q3 '25
Net income โ$27.1M
Q4 '25
Net income โ$46.1M
Q1 '26
Net income โ$44.5M
Q2 '26
Net income โ$43.4M
FY20
Diluted EPS โ$23.65
FY21
Diluted EPS โ$2.96
FY22
Diluted EPS โ
FY23
Diluted EPS โ
FY24
Diluted EPS โ
FY25
Diluted EPS โ
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ
Return on assets โ72.7%
FY21
Return on capital โ
Return on equity โ49.5%
Return on assets โ35.6%
FY22
Return on capital โ
Return on equity โ35.1%
Return on assets โ30.6%
FY23
Return on capital โ
Return on equity โ60.1%
Return on assets โ41.9%
FY24
Return on capital โ
Return on equity โ36.2%
Return on assets โ19.6%
FY25
Return on capital โ
Return on equity โ16.9%
Return on assets โ8.7%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$27.5M in fiscal 2025, โ22.2% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$26.4M
FY21
Free cash flow โ$69.1M
FY22
Free cash flow โ$105M
FY23
Free cash flow โ$62.8M
FY24
Free cash flow $38.0M
FY25
Free cash flow โ$27.5M
Q3 '23
Free cash flow โ$26.4M
Q4 '23
Free cash flow $27.9M
Q1 '24
Free cash flow โ$39.5M
Q2 '24
Free cash flow โ$29.8M
Q3 '24
Free cash flow โ$21.4M
Q4 '24
Free cash flow $129M
Q1 '25
Free cash flow โ$47.1M
Q2 '25
Free cash flow โ$36.4M
Q3 '25
Free cash flow $99.8M
Q4 '25
Free cash flow โ$43.8M
Q1 '26
Free cash flow โ$39.2M
Q2 '26
Free cash flow โ$48.8M
FY20
Cash from operations โ$23.1M
Capital spending $3.4M
FY21
Cash from operations โ$59.4M
Capital spending $9.7M
FY22
Cash from operations โ$92.5M
Capital spending $12.9M
FY23
Cash from operations โ$43.8M
Capital spending $19.0M
FY24
Cash from operations $42.0M
Capital spending $4.0M
FY25
Cash from operations โ$22.8M
Capital spending $4.7M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$24.7M
Capital spending $1.7M
Q4 '23
Cash from operations $29.6M
Capital spending $1.7M
Q1 '24
Cash from operations โ$38.2M
Capital spending $1.4M
Q2 '24
Cash from operations โ$27.8M
Capital spending $2.0M
Q3 '24
Cash from operations โ$21.0M
Capital spending $0.4M
Q4 '24
Cash from operations $129M
Capital spending $0.2M
Q1 '25
Cash from operations โ$45.5M
Capital spending $1.6M
Q2 '25
Cash from operations โ$34.7M
Capital spending $1.7M
Q3 '25
Cash from operations $100M
Capital spending $0.7M
Q4 '25
Cash from operations โ$43.0M
Capital spending $0.8M
Q1 '26
Cash from operations โ$37.4M
Capital spending $1.9M
Q2 '26
Cash from operations โ$44.1M
Capital spending $4.7M
Cash from operations
Capital spending
Dividends, buybacks and share count
Monte Rosa Therapeutics, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 12.4%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends $0.0M
Buybacks โ
FY22
Dividends $0.0M
Buybacks โ
FY23
Dividends $0.0M
Buybacks โ
FY24
Dividends $0.0M
Buybacks โ
FY25
Dividends $0.0M
Buybacks โ
Dividends
Buybacks
Q3 '23
Dividends $0.0M
Buybacks โ
Q4 '23
Dividends $0.0M
Buybacks โ
Q1 '24
Dividends $0.0M
Buybacks โ
Q2 '24
Dividends $0.0M
Buybacks โ
Q3 '24
Dividends $0.0M
Buybacks โ
Q4 '24
Dividends $0.0M
Buybacks โ
Q1 '25
Dividends $0.0M
Buybacks โ
Q2 '25
Dividends $0.0M
Buybacks โ
Q3 '25
Dividends $0.0M
Buybacks โ
Q4 '25
Dividends $0.0M
Buybacks โ
Q1 '26
Dividends $0.0M
Buybacks โ
Q2 '26
Dividends $0.0M
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.03B
FY22
Diluted shares 0.05B
FY23
Diluted shares 0.05B
FY24
Diluted shares 0.07B
FY25
Diluted shares 0.08B
Balance sheet
Cash, debt and the ratios that show how comfortably Monte Rosa Therapeutics, Inc. can carry it.
FY20
Cash $41.7M
Debt โ
FY21
Cash $346M
Debt โ
FY22
Cash $54.9M
Debt โ
FY23
Cash $128M
Debt โ
FY24
Cash $224M
Debt โ
FY25
Cash $130M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $346M | $54.9M | $128M | $224M | $130M |
| Current ratio | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Quick ratio | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Total assets | $366M | $342M | $304M | $439M | $449M |
| Total liabilities | $18.8M | $71.0M | $125M | $216M | $216M |
| Shareholders' equity | $348M | $271M | $179M | $223M | $233M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | 4 / 7 | 4 / 7 |
| Accruals ratio | โ26.0% | โ7.0% | โ4.5% | โ28.3% | โ30.9% | โ3.6% |
| Altman Z'' | โ6.77 | 22.92 | 4.41 | โ1.49 | โ0.12 | 1.67 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | โ | โ | โ | $0.0M | $75.6M | $124M |
| Research and development | $24.0M | $57.2M | $85.1M | $111M | $122M | $142M |
| Operating income | โ$28.0M | โ$72.9M | โ$112M | โ$143M | โ$81.1M | โ$54.2M |
| Pretax income | โ$10.1M | โ$9.9M | โ$109M | โ$135M | โ$70.1M | โ$39.7M |
| Income tax | โ | โ | $0.0M | $0.3M | $2.6M | โ$1.1M |
| Net income | โ$35.9M | โ$74.0M | โ$109M | โ$135M | โ$72.7M | โ$38.6M |
| Diluted EPS | โ$23.65 | โ$2.96 | โ | โ | โ | โ |
| Diluted shares | 0.00B | 0.03B | 0.05B | 0.05B | 0.07B | 0.08B |
| Cash flow | ||||||
| Cash from operations | โ$23.1M | โ$59.4M | โ$92.5M | โ$43.8M | $42.0M | โ$22.8M |
| Capital expenditure | $3.4M | $9.7M | $12.9M | $19.0M | $4.0M | $4.7M |
| Free cash flow | โ$26.4M | โ$69.1M | โ$105M | โ$62.8M | $38.0M | โ$27.5M |
| Depreciation and amortization | $0.5M | $2.1M | $3.7M | $6.2M | $8.1M | $8.4M |
| Stock-based compensation | $0.4M | $5.2M | $11.7M | $16.7M | $18.1M | $18.9M |
| Dividends paid | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||
| Cash and short-term investments | $41.7M | $346M | $54.9M | $128M | $224M | $130M |
| Finance lease liabilities | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $43.6M | $349M | $276M | $236M | $377M | $393M |
| Current liabilities | $29.3M | $16.6M | $25.6M | $46.6M | $157M | $64.2M |
| Property and equipment, net | $4.6M | $12.3M | $27.1M | $33.8M | $29.5M | $26.0M |
| Total assets | $49.4M | $366M | $342M | $304M | $439M | $449M |
| Total liabilities | $30.3M | $18.8M | $71.0M | $125M | $216M | $216M |
| Preferred stock | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | โ$48.7M | $348M | $271M | $179M | $223M | $233M |
| Margins | ||||||
| Operating margin | โ | โ | โ | โ | โ107.3% | โ43.8% |
| EBITDA margin | โ | โ | โ | โ | โ96.5% | โ37.1% |
| Net margin | โ | โ | โ | โ | โ96.1% | โ31.2% |
| FCF margin | โ | โ | โ | โ | 50.3% | โ22.2% |
| Returns | ||||||
| Return on capital employed | โ139.3% | โ20.8% | โ35.5% | โ55.7% | โ28.8% | โ14.1% |
| Return on equity | โ | โ49.5% | โ35.1% | โ60.1% | โ36.2% | โ16.9% |
| Return on assets | โ72.7% | โ35.6% | โ30.6% | โ41.9% | โ19.6% | โ8.7% |
| Return on tangible equity | โ | โ21.3% | โ40.0% | โ75.5% | โ32.6% | โ16.6% |
| Growth | ||||||
| Revenue growth | โ | โ | โ | โ | โ | 63.5% |
| FCF growth | โ | โ | โ | โ | โ | โ172.3% |
| Share count change | โ | 1,548.1% | 88.9% | 8.8% | 43.8% | 12.4% |
| Financial health | ||||||
| Current ratio | 1.5x | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Quick ratio | 1.5x | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Capital allocation | ||||||
| Capex / revenue | โ | โ | โ | โ | 5.3% | 3.8% |
| Stock comp / revenue | โ | โ | โ | โ | 24.0% | 15.3% |
| Payouts / FCF | โ | โ | โ | โ | 0.0% | โ |
| Quality scores | ||||||
| Piotroski F-score | โ | โ | โ | โ | 4.0 | 4.0 |
| Altman Z'' | โ6.8 | 22.9 | 4.4 | โ1.5 | โ0.1 | 1.7 |
| Accruals ratio | โ26.0% | โ7.0% | โ4.5% | โ28.3% | โ30.9% | โ3.6% |
Source: SEC EDGAR XBRL filings (CIK 0001826457). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.